Vertex Pharmaceuticals

Cell and gene therapy / small-molecule therapeutics

VRTX · Nasdaq · United States

Share price · VRTX

$536.45+8.26 (+1.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VRTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-4.0%
  2. 30 Oct 2026+3.5%

    Nothing announced by VRTX that day or the session before.

  3. 22 Oct 2026+2.0%
  4. 10 Aug 2026+5.6%

    Nothing announced by VRTX that day or the session before.

  5. 8 Jul 2026-4.6%
  6. 2 Jul 2026+6.0%
  7. 10 Mar 2026+8.3%
  8. 17 Feb 2026-2.9%
  9. 13 Feb 2026+5.7%
  10. 3 Dec 2025+6.9%

Share of unusual movement by asset

For each asset, the share of VRTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vanzacaftor / tezacaftor / deutivacaftor (Alyftrek)
events and moves
6shown from 8 days
Exagamglogene autotemcel (Casgevy) (Casgevy)
events and moves
4shown from 8 days
Suzetrigine (Journavx)
events and moves
3shown from 8 days
Povetacicept
events and moves
2shown from 8 days
VX-264
events and moves
1shown from 8 days
Inaxaplin
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—61%

Assets

(15 total)
15Total Assets
7Approved
2Phase 3 / Filed
6Phase 1–2 / Early
13Diseases
Quick filter:
Showing 15 of 15 assets
Target & Modality
Approved
CFTR · CFTRSmall molecule
Cystic Fibrosis
Approved
BCL11A erythroid enhancer (gene editing)Gene therapy / editing
Sickle Cell DiseaseBeta-Thalassemia
Transfusion-Dependent Beta Thalassemia
Ivacaftor(Kalydeco)
Approved
CFTRSmall molecule
Cystic Fibrosis
lumacaftor(Orkambi)
Approved
CFTRSmall molecule
Cystic Fibrosis
Suzetrigine(Journavx)
Approved
Voltage-gated sodium channel NaV1.8Small molecule
Diabetic Peripheral Neuropathic PainAcute Pain
Approved
CFTRSmall molecule
Cystic Fibrosis
Approved
CFTR · CFTRSmall molecule
Cystic Fibrosis
Phase 3
BAFF / APRILProtein / enzyme therapeutic
Myasthenia GravisIgA NephropathyPrimary Membranous Nephropathy
Phase 3
Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug) · Pancreatic islet cell replacementCell therapy
Type 1 Diabetes
Phase 2/3
APOL1 (Apolipoprotein L1)Small molecule
Chronic Kidney DiseaseAPOL1-Mediated Kidney Disease
Phase 2
Polycystin-1 (PKD1 variants)Small molecule
Autosomal Dominant Polycystic Kidney Disease
Phase 2
DMPK CUG-repeat RNARNA / oligonucleotide
Myotonic Dystrophy Type 1
Phase 2
Voltage-gated sodium channel NaV1.8Small molecule
Diabetic Peripheral Neuropathic Pain
Phase 1
CFTRSmall molecule
Cystic Fibrosis
Discontinued
Pancreatic islet cell replacementCell therapy
Indication not yet linked

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (14)
January 2027 (1)
Suzetrigine · JournavxPhase 3Diabetic Peripheral Neuropathic Pain
Est. primary completion 2027-01-25 · NCT06696443 · CT.gov ↗
What to watch
February 2027 (1)
VX-670Phase 1/2Myotonic Dystrophy Type 1 (DM1)
Est. primary completion 2027-02-02 · NCT06185764 · CT.gov ↗
What to watch
March 2027 (2)
VX-264Phase 1/2Type 1 Diabetes
Est. primary completion 2027-03-12 · NCT05791201 · CT.gov ↗
What to watch
VX-993Phase 2Diabetic Peripheral Neuropathic Pain
Est. primary completion 2027-03-25 · NCT06619860 · CT.gov ↗
What to watch
April 2027 (2)
Est. primary completion 2027-04-06 · NCT05331183 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3Diabetic Peripheral Neuropathic Pain
Est. primary completion 2027-04-06 · NCT07231419 · CT.gov ↗
What to watch
May 2027 (1)
Suzetrigine · JournavxPhase 3Diabetic Peripheral Neuropathic Pain
Est. primary completion 2027-05-31 · NCT06628908 · CT.gov ↗
What to watch
June 2027 (2)
Exagamglogene autotemcel (Casgevy)Phase 3Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Est. primary completion 2027-06-06 · NCT05329649 · CT.gov ↗
What to watch
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
Est. primary completion 2027-06-09 · NCT05477563 · CT.gov ↗
What to watch
July 2027 (1)
VX-407Phase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Est. primary completion 2027-07-22 · NCT07161037 · CT.gov ↗
What to watch
September 2027 (1)
Est. primary completion 2027-09-30 · NCT06460506 · CT.gov ↗
What to watch
November 2027 (1)
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Est. primary completion 2027-11-14 · NCT05356195 · CT.gov ↗
What to watch
December 2027 (2)
PovetaciceptPhase 3Immunoglobulin A Nephropathy
Est. primary completion 2027-12-12 · NCT07890909 · CT.gov ↗
What to watch
ZimislecelPhase 3Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Est. primary completion 2027-12-31 · NCT04786262 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
PovetaciceptPhase 3Immunoglobulin A Nephropathy
Est. primary completion 2028-01-30 · NCT06564142 · CT.gov ↗
What to watch
June 2028 (1)
InaxaplinPhase 2/3Proteinuric Kidney Disease
Est. primary completion 2028-06-02 · NCT05312879 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
VX-670Phase 2Myotonic Dystrophy Type 1 (DM1)
Est. primary completion 2029-01-30 · NCT06926621 · CT.gov ↗
What to watch
March 2029 (1)
PovetaciceptPhase 2Myasthenia Gravis, Generalized
Est. primary completion 2029-03-02 · NCT07501702 · CT.gov ↗
What to watch
June 2029 (1)
PovetaciceptPhase 2/3Primary Membranous Nephropathy
Est. primary completion 2029-06-27 · NCT07204275 · CT.gov ↗
What to watch
July 2029 (1)
Est. primary completion 2029-07-30 · NCT05844449 · CT.gov ↗
What to watch
December 2029 (1)
PovetaciceptPhase 3Immunoglobulin A Nephropathy
Est. primary completion 2029-12-28 · NCT07807995 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Est. primary completion 2030-06-30 · NCT05422222 · CT.gov ↗
What to watch
2039 (1)
September 2039 (1)
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Est. primary completion 2039-09-30 · NCT04208529 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(15)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

30 November 2026FDA action datePovetaciceptPDUFA date 30 November 2026 for povetacicept in IgAN
US, FDA · Vertex Pharmaceuticals · Source ↗

Recent

22 September 2026Topline resultInaxaplinPhase 2b AMPLIFIED (NCT06794996): UACR fell 42.7% (cohort 1) and 17.3% (cohort 2) from baseline at Week 13
Vertex Pharmaceuticals · Source ↗
1 July 2026ApprovalExagamglogene autotemcel (Casgevy)FDA approves expanded use of CASGEVY for ages 2 and older
US, FDA · Source ↗
11 June 2026Filing submittedExagamglogene autotemcel (Casgevy)UK submission to expand CASGEVY use to younger children
UK, MHRA · Source ↗
5 June 2026Topline resultVanzacaftor / tezacaftor / deutivacaftorPhase 3 ALYFTREK data in children ages 2 to 5 with CF
1 June 2026Filing acceptedPovetaciceptFDA accepts povetacicept BLA for accelerated approval in IgAN
US, FDA · Vertex Pharmaceuticals · Source ↗
June 2026Filing submittedElexacaftor / tezacaftor / ivacaftorVertex begins global regulatory submissions for TRIKAFTA in children aged 1 to under 2 years
Vertex Pharmaceuticals Incorporated · Source ↗
28 March 2025Topline resultVX-264Phase 1/2 study of VX-264 (NCT05791201) did not meet its efficacy endpoint; programme discontinued
Vertex Pharmaceuticals · Source ↗
30 January 2025FDA action dateSuzetriginePDUFA target date set
US, FDA · Source ↗
2 January 2025FDA action dateVanzacaftor / tezacaftor / deutivacaftorPDUFA target action date set
US, FDA · Source ↗
30 July 2024Filing acceptedSuzetrigineFDA accepts suzetrigine NDA
US, FDA · Source ↗
30 July 2024Priority reviewSuzetrigineFDA grants priority review
US, FDA · Source ↗
2 July 2024Filing acceptedVanzacaftor / tezacaftor / deutivacaftorFDA accepts NDA for vanzacaftor/tezacaftor/deutivacaftor
US, FDA · Source ↗

The 12 most recent of 14 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.4B$1.3B$5.0B+ $1.3B short-term inv.—$643M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.3B$994M$6.1B+ $1.7B short-term inv.—$1.1B operating cash flowreport ↗
2026-Q1$3.0B$962M$5.5B+ $1.8B short-term inv.—$1.4B operating cash flowreport ↗
2025-Q3$3.1B$978M$4.9B+ $1.3B short-term inv.—$1.2B operating cash flowreport ↗
2025-Q2$3.0B$978M$5.0B+ $1.4B short-term inv.—$1.1B operating cash flowreport ↗
2025-Q1$2.8B$980M$4.7B+ $1.5B short-term inv.—$819M operating cash flowreport ↗
2024-Q3$2.8B$876M$5.2B+ $1.3B short-term inv.—$1.4B operating cash flowreport ↗
2024-Q2$2.6B$967M$4.6B+ $1.2B short-term inv.$3.6B-$3.8B operating cash flowreport ↗
2024-Q1$2.7B$789M$9.2B+ $1.0B short-term inv.—$1.3B operating cash flowreport ↗
2023-Q3$2.5B$810M$11.1B+ $818M short-term inv.—$1.3B operating cash flowreport ↗
2023-Q2$2.5B$786M$10.2B+ $1.1B short-term inv.—$1.1B operating cash flowreport ↗
2023-Q1$2.4B$743M$9.3B+ $1.1B short-term inv.—$900M operating cash flowreport ↗
2022-Q3$2.3B$645M$9.2B+ $599M short-term inv.—$956M operating cash flowreport ↗
2022-Q2$2.2B$600M$8.7B+ $551M short-term inv.—$1.1B operating cash flowreport ↗
2022-Q1$2.1B$601M$7.6B+ $638M short-term inv.—$956M operating cash flowreport ↗
2021-Q3$2.0B$467M$6.3B+ $685M short-term inv.—$927M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$12.0B$3.9B$5.1B+ $1.5B short-term inv.—$3.6B operating cash flowreport ↗

Vertex reported full-year 2025 revenue of $12,001.3M, up 8.9% YoY, with R&D spend of $3,909.5M, up 7.7% YoY. Cash and equivalents stood at $5,084.8M, and net income was $3,953.2M.

The company guided full-year 2026 total revenue to $12.95B-$13.1B, including $500M or more from non-CF products. Pipeline progress includes the ongoing rolling BLA for povetacicept in IgAN, with completion expected in H1 2026, and multiple mid- and late-stage programs advancing; CASGEVY generated $116M in 2025 revenue, and JOURNAVX saw more than 550,000 prescriptions filled since launch.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$11.0B$3.6B$4.6B+ $1.5B short-term inv.$134M-$493M operating cash flowreport ↗
2023-FY$9.9B$3.2B$10.4B+ $849M short-term inv.—$3.5B operating cash flowreport ↗
2022-FY$8.9B$2.5B$10.5B+ $275M short-term inv.—$4.1B operating cash flowreport ↗
2021-FY$7.6B$1.9B$6.8B+ $730M short-term inv.—$2.6B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 91 sales ($140.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Bhatia Sangeeta N. · directorOpen-market sale271$547.86$148KForm 4
2026-11-16Thornberry Nancy · directorOpen-market sale1,000$547.86$548KForm 4
2026-11-12WAGNER CHARLES F JR · EVP, CO & FOOpen-market sale15,286$547.87$8.4MForm 4
2026-11-06Kewalramani Reshma · director, CEO & PresidentOpen-market sale11,866$531.53$6.3MForm 4
2026-10-20Brennan Daniel J. · directorAward / grant795$503.47$400KForm 4
2026-10-15Garber Alan M · directorAward / grant (derivative)29.272$512.44$15KForm 4
2026-10-15SACHS BRUCE I · directorAward / grant (derivative)92.694$512.44$48KForm 4
2026-09-08van Grunsven Jasper · EVP, CP and NPPOAward / grant8,682——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,663 reporting institutions held 232.0M shares ($101.2B, 91.5% of shares outstanding).

#InstitutionSharesValue
1Capital World Investors25,368,124$11.3B
2BlackRock, Inc.23,969,517$10.7B
3Capital Research Global Investors21,125,964$9.4B
4VANGUARD CAPITAL MANAGEMENT LLC16,512,810$7.4B
5STATE STREET CORP11,730,139$5.2B
6JPMORGAN CHASE & CO7,033,156$3.1B
7GEODE CAPITAL MANAGEMENT, LLC6,139,621$2.7B
8VANGUARD PORTFOLIO MANAGEMENT LLC5,145,609$2.3B
9Capital International Investors5,126,077$2.3B
10LOOMIS SAYLES & CO L P4,003,821$1.8B
11ALLIANCEBERNSTEIN L.P.3,910,786$1.8B
12WELLINGTON MANAGEMENT GROUP LLP3,212,589$1.4B
13MORGAN STANLEY3,188,881$1.4B
14UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,057,396$1.4B
15BANK OF AMERICA CORP /DE/2,878,183$1.3B